Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Spirovant Sciences

Pre-clinical

Pre-clinical

Therapeutic Approach

Restore CFTR Function

This program is working to advance inhaled adeno-associated virus (AAV) delivery of the CFTR gene to the lungs. This would allow the lung cells to create normally functioning CFTR protein, regardless of an individual’s specific CFTR gene mutation. 

Status

Laboratory studies to develop and test this potential therapy are underway.

Sponsor

This program is sponsored by Spirovant Sciences (formerly Talee Bio) and partially funded by the Cystic Fibrosis Foundation.



Contact us about Spirovant Sciences >